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Background: Chemotherapy is a common treatment for leukemia as well as in other cancer treatment. The lack of tumor 
selectivity and development of multi-drug resistance by chemotherapy caused the development of new strategy in cancer 
treatment become a pressing need. This study was performed to evaluate the anticancer activity and selectivity of seven 
derivatives of chalcones against K562 and HL-60 leukemia cell lines. 
Materials and Methods: The cytotoxicity of chalcone’s seven derivatives (compound 1-7) was tested by using 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) method. The 
percentage of cell mortality data was calculated then the IC50 was analyzed using probit analysis (SPSS 17). The selectivity 
index (SI) then calculated from IC50 ratio of normal lymphocyte cells and cancerous cells line (HL-60 and K562). 
Results: The IC50 of almost all seven tested compounds were lower in HL-60 cell lines (ranged from 1.57 to 9.63 µg/mL) than 
K562 cell lines (ranged from 5.87 to 52.56 µg/mL), except for Compound 7 (5.87±0.15 µg/mL).  The number and position of 
methoxy groups in chalcone derivatives influenced the anticancer and cancer selectivity of chalcone derivatives. 
Conclusion: The results revealed that the number and position of methoxy groups in chalcone derivatives influenced the 
anticancer and cancer selectivity of chalcone derivatives. 
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Introduction
Leukemia is cancer of the white blood cells characterized by 
widespread, rapid, and disorderly proliferation of leukocytes 
and their precursor as well as by the presence of immature 
leukocytes in blood often in very large number.1,2 Although 
leukemia is a rare disease, however it exceeds a cause of 
death from many of the acute communicable diseases 
due to its fatal character.2 In 2012, leukemia suffered by 
approximately 352,000 people around the world and caused 
265,000 death.3
 Chemotherapy is common for the treatment of 
leukemia as well as other cancer.4 Nowaday, chemotherapy 
is one of the most effective and potent strategies to treat 
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cancer. However, the use of anticancers in the chemotherapy 
is limited. All the anticancer currently available have severe 
side effects on normal cells due to their nonspecifity. In 
addition, the resistance of cancer cells to the anticancer 
remains a significant impediment to successful 
chemotherapy.5 Therefore, the need to discover and develop 
new anticancers with specific target and novel mechanisms 
is urgent.
 Natural products are important and valuable resources 
for anticancer discovery and development. Natural 
products demonstrate important structural diversity and 
offer a wide variety of novel compounds with novel 
anticancer mechanims.6,7 Vincristine, irinotecan, paclitaxel, 
actinomycin D, mitomycin C, and doxorubicin are classic 
examples of natural-derived anticancer that used in clinic. 
During the last few years, natural-product-based drug 
discovery is increasing based on new technologies, such as 
combinatorial synthesis and high-throughput screening, and 
their associated approaches.6 
 Chalcones are precusor of flavonoids that widely 
distributed in plants and one of potential natural compounds 
to develop as anticancer. A number of chalcones have been 
isolated or synthesized and evaluated for their cytotoxicity 
on cancer cell lines culture and their anticancer activity 
on cancer animal model.8,9 Furthermore, the molecular 
mechanisms of anticancer action of chalcones have also 
investigated. The chalcones exhibited anticancer activity 
through multiple mechanisms included cell cycle disruption, 
angiogenesis inhibition, tubulin polymerization inhibition, 
apoptosis induction and blockade of nuclear factor-kappa B 
(NF-κB) signaling pathway.9-13 
 In our previous study, some derivatives of methoxy 
amino chalcone have been synthesized and evalauated for 
their cytotoxicity on breast cancer cell culture.14,15 In this 
study we evaluated the cytotoxicity of the methoxy amino 
chalcone derivatives on  (human acute promyelocytic 
leukemia (HL-60) and human chronic myelogenous 
leukemia (K562) cells line. The cytotoxicity of these 
derivatives on normal lymphocyte cells was also evaluated 
in order to determine thier selectivity index (SI).
Materials and methods
Tested Compounds
The methoxy amino chalcone derivatives were synthesized 
by Drs. Hery Suwito in the Department of Chemistry, 
Faculty of Science and Technology, Airlangga University, 
Surabaya, Indonesia. The chemical structure of the methoxy 
amino chalcone derivatives are showed in Table 1.
Cell Culture
The HL-60 cell line, K562 cell line and limphocytes were 
used for cytotoxic screening of the tested compounds. 
The HL-60 and K562 cell lines were obtained from Stem 
Cells and Cancer Institute (SCI) Jakarta, Indonesia. The 
cell lines were maintained in Iscove's Modified Dulbecco's 
(IMD)  medium supplemented by 10% fetal bovine serum 
(FBS), and 2% penicilin-streptomycin. The cell lines were 
maintained at 37°C in a 5% CO2 atmosphere with 95% 
humidity. Lymphocytes were isolated from whole blood 
using Histopaque (Sigma) according to the manufacturer’s 
instructions. The lymphocytes culture were then maintained 
in RPMI1640 medium supplemented with 1% non-essential 
amino acids, 1% L-glutamine,  100 U/mL penicillin, 10 mg/
mL streptomycin and 10% heat inactivated fetal calf serum 
at 37°C in in a 5% CO2 atmosphere with 95% humidity.
Cytotoxic Assay
Cytotoxic activity of the tested compounds on the treated 
cells were determined using the 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxyme-thoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) colorimetric assay developed by Yoon, 
et al.,16 and Khan, et al.,17 after modification. Around 90 μL 
of the treated cells culture at density of 104 cells/well were 
distributed in 96-wells plates. Ten microlitres of the tested 
compounds at various concentration (0.2-100 µg/mL) then 
added to each well, except for the negative control the well 
was added with the culture medium and for the positive 
control the well was added with imatinib or accutane. 
The plate then incubated for 24 h at 37°C in a 5% CO2. 
Following the incubation, the mixture further added with 20 
µL of MTS, incubated for 4 h at 37°C in 5% of CO2. The 
absorbance then measured at λ of 490 nm using a microplate 
reader.18 The cell growth inhibition was determined with the 
equation:
 % of cell growth inhibition = OD of control cell - OD of treated cell 
        OD of control cell  x 100%
For this MTS method, IC50 (concentration that inhibit 50% 
cell growth) values were determined using probit analysis. 
The IC50 values was obtained from three independent 
experiments. Furthermore, selectivity index (SI) was 
determined from the IC50 ratio of lymphocytes normal 
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Compound Chemical name R1 R2 R3 R4
1 (E)-1-(4-aminophenyl)-3-(2-
methoxyphenyl)-prop-2-en-1-one
OCH3 H H H
2 (E)-1-(4-aminophenyl)-3-(3-
methoxyphenyl)-prop-2-en-1-one
H OCH3 H H
3 (E)-1-(4-aminophenyl)-3-(4-
methoxyphenyl)-prop-2-en-1-one)
H H OCH3 H
4 (E)-1-(4-aminophenyl)-3-(2,3 
dimethoxyphenyl)-prop-2-en-1-one
OCH3 OCH3 H H
5 (E)-1-(4-aminophenyl)-3-(2,4 
dimethoxyphenyl)-prop-2-en-1-one
OCH3 H OCH3 H
6 (E)-1-(4-aminophenyl)-3-(2,5- 
dimethoxyphenyl)-prop-2-en-1-one
OCH3 H H OCH3
7 (E)-1-(4-aminophenyl)-3-phenylprop-
2-en-1-one)
H H H H
Methoxy amino chalcone structure
Table 1. Chemical structure of different methoxy amino chalcone derivatives.
and cancerous cells (K562 and HL-60). The SI value 
demonstrates selectivity of the tested compound to the cell 
lines tested. Samples with SI value greater than 2 were 
considered to have good selectivity.19
 
Statistical Analysis
Data of the IC50 values and SI were presented as mean ± 
standard deviation (SD) and were analyzed using Tukey’s 
HSD Post Hoc. A p-value less than 0.05 was considered as 
statistically significant.
Results
Growth inhibition of K562, HL-60 cells and lymphocytes 
after incubation with the tested compounds in various 
concentrations are presented in Figure 1. The growth 
inhibition in a dose-dependent manner was observed in all the 
treated cells by all the tested compounds. At concentration 
of 100 µg/mL, all the tested compounds exhibited more than 
70% growth inhibition against the K562 and HL-60 cell 
lines. Growth inhibition of the lymphocytes after incubation 
with the tested compounds at the same concentration were 
lower than that of the HL-60 cells. It was indicated that 
the tested compounds more sensitive to the HL-60 cells. 
The effect of tested compounds toward the K562, HL-60, 
and lymphocytes cells can be seen in Figure 2, 3 and 4, 
respectively. It can be seen that mainly the treated cells have 
lower density than the normal cells. 
 The cytotoxic activity of the tested compounds against 
the leukemia cell lines and lymphocytes are presented in 
Table 2. All seven tested compounds showed moderate 
cytotoxic activity with IC50 values ranged from 5.87 to 52.56 
µg/mL against K562 cell line and from 1.57 to 9.63 µg/mL 
against HL-60 cell line. Among all seven tested compounds, 
compound 7 showed the most cytotoxic against K562 cell 
line with the IC50 value of 5.87 ± 0.15 µg/mL, whereas the 
compound 4 showed the most cytotoxic against HL-60 cell 
line with the IC50 value of  1.57 ± 0.40 µg/mL. 
  The SI of the tested compounds are presented 
in Table 2. Almost all tested compounds showed low 
selectivity with SI values ranged from 0.05 to 0.96 toward 
K562 cell line and from 0.45 to 5.26 toward HL-60 cell line. 
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Figure 1. Growth inhibition after 
incubation with the tested compounds. 
Growth inhibition of K562 cells (A), HL-
60 cells (B) and  lymphocytes (C) after 
incubation with the tested compounds 
for 24 h.
In comparison, the positive control imatinib showed high 
selectivity (SI>2) toward both HL-60 and K562 cell line, 
however accutane showed low selectivity toward K562 cell 
line. Among all seven tested compounds, the compound 
4 showed the highest selectivity toward HL-60 and K562 
cell line with SI value of 5.26 and 0.96 respectively, higher 
than those of imatinib and accutane toward the HL-60 but 
still lower than imatinib toward the K562 cell line. The 
compound  5  showed  the  lowest  selectivity  toward  K562 
cell line with SI value of 0.05, whereas the compound 7 
showed the lowest selectivity toward HL-60 with SI value 
of 0.45.
Discussion
The therapeutic activity of most anticancer drugs in clinical 
use is limited by their general toxicity to proliferating 
cells, including some normal cells. Researcher continue 
to develop novel cytotoxic agent with unique mechanisms 
of action, but many of that compounds still lack of tumor 
selectivity and have not been therapeutically useful.20 Some 
chalcone derivatives have been synthesized and evaluated 
for their cytotoxic activity. Various chalcones can inhibit 
different steps of carcinogenesis from the very early stages, 
including tumor initiation trough promotion, progression, 
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Figure 2. Morphological appearance of K562 cells with no treatment (normal cells) and cells with treatment at concentration 100 
µg/mL. Treatment cells are compound 1 (A), compound 2 (B), compound 3 (C), compound 4 (D), compound 5 (E), compound 6 (F), 
compound 7 (G), imatinib (H) and accutan (I). The normal cells relatively has higher density than treated cells. White scale bar: 200 µM. 
angiogenesis, and invasion, to the very large states 
leading to metastasis. Synthesis or chemical modification 
of chalcones allows rapid generation of large number of 
novel compounds for anti-cancer.21 Chalcones contain a 
common 1,3-diphenyl, propenone template that can be 
modified through addition of functional groups such as 
aryls, halogens, hydroxyls, carboxylic groups, benzena,etc 
to alter the biological potential. The chemical structure of 
chalcone appears  to  play  critical  role  in  determining 
their molecular  targets.22 In this study, seven chalcone 
derivatives compounds cytotoxic activity and selectivity 
was tested against  K562  and  HL-60  cells  line,  then 
compared with the activity of cancer drugs imatinib and 
accutane. 
 The seven derivatives compounds of chalcones 
exerted cytotoxic activity against K562 and HL-60 cell 
lines in concentration-dependent manner. Compound 
4 and 7 showed highest cytotoxicity against K562 cell 
lines, comparable with those of imatinib (p>0.05) and 
better than accutane (p<0.05). Compound 4 also showed 
highest cytotoxicity against HL-60 cell lines, followed 
by Compound 1 and 6 with activity were higher than 
both imatinib and accutane (p<0.05). This study was in 
accordance with Suwito, et al., study results that Compound 
K562 HL-60 Lymphocytes K562 HL-60
1 10.83 ± 0.67b 1.76 ± 0.20a 2.92 ± 1.15a 0.27 1.66
2 21.46 ± 0.30c 7.81 ± 1.21b 10.78 ± 2.09ab 0.5 1.38
3 48.45 ± 5.37e 6.92 ± 1.18b 9.13 ± 4.12ab 0.19 1.32
4 8.65 ± 0.93ab 1.57 ± 0.40a 8.26 ± 2.29ab 0.96 5.26
5 52.56 ± 1.79e 2.49 ± 0.84a 2.46 ± 0.96a 0.05 0.99
6 11.84 ± 1.11b 1.84 ± 0.41a 3.51 ± 0.37ab 0.3 1.91
7 5.87 ± 0.15ab 9.63 ± 2.32b 4.33 ± 0.97ab 0.74 0.45
Imatinib 2.67 ± 0.53a 16.59 ± 0.77c 42.30 ± 17.11c 15.85 2.55
Accutane 39.47 ± 3.14d 7.82 ± 0.92b 20.44 ± 3.72b 0.52 2.61
Compound 
number
IC50 ± SD (µg/mL) Selectivity Index (SI)
Table 2.  Cytotoxic activity of the tested compounds against the leukemia cell lines (K562 
and Hl-60) and lymphocytes and their selectivity index.
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Figure 3. Morphological appearance of HL-60 cells with no treatment (normal cells) and cells with treatment at concentration 
100 µg/mL. Treatment cells are compound 1 (A), compound 2 (B), compound 3 (C), compound 4 (D), compound 5 (E), compound 6 (F), 
compound 7 (G), imatinib (H) and accutan (I). The normal cells relatively has higher density than treated cells. White scale bar: 200 µM. 




Figure 4. Morphological appearance of lymphocyte cells with no treatment (normal cells) and cells with treatment at concentration 
100 µg/mL. Treatment cells are compound 1 (1), compound 2 (2), compound 3 (3), compound 4 (4), compound 5 (5), compound 6 (6), 
compound 7 (7), imatinib (8) and accutan (9). The normal cells relatively has higher density than treated cells. White scale bar: 200 µM. 
7, 4 and 6 exhibited strongest antiproliferative activity 
respectively among chalcone derivatives tested against 
T47D (breast cancer cells). The methoxy-4’amino chalcone 
performed better antiproliferative activity compared to 
methoxy chalcone derivatives and methoxy-4’-bromo 
chalcone derivatives.15 These results revealed that amino 
group attached in 4’ position played an important role in the 
growth inhibition of the cancer cells. 
 It has been postulated that the presence of 4-amino 
group on first phenyl ring of the chalcones increases their 
activity and thus their anti-proliferative activity.23,24  The IC50 
of almost all seven tested compounds were lower in HL-60 
cell lines than K562 cell lines, except for Compound 7. K562 
is a kind chronic myeloid leukemia that occurs in blastic 
myeloid transformation which tends to be more aggressive 
and treatment resistant than other leukemia.25 These results 
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confirmed that HL-60-human acute promyelocytic leukemia 
cells are more sensitive than K562 cells.26 
 Our study also confirmed that the number and the 
position of methoxy group play a role in the chalcone 
derivatives compound anticancer activity.  Two coumarin-
containing chalcone compounds were compared, compound 
with a methoxy group at R3 presented increased levels 
of inhibition. Activity is due to methoxy group in the 
architecture.27 Methoxylated chalcones are structurally 
similar to combretastatin A-4-5 and colchicine that bind 
to the tubulin effectively.28,29  Several other studies also 
suggested that the number and the position of methoxy 
substituents on the aromatic rings appeared to be critical for 
cytotoxicity.9 Generally, all the seven tested compounds had 
low selectivity toward K562 cells with all SI values below 
2 indicate the compounds had general toxicity to cells.19 
However, Compound 4 showed high selectivity toward HL-
60 cells, suggesting it have better potential to be use for 
acute promyelocytic leukemia. 
 The mechanism of anti-tumor of chalcones remains 
to be fully clarified.30 Some studies reported that chalcone 
possess the anticancer activity toward HTC116 colon 
carcinoma cells31, leukemia cells (K56232 and HL-608), 
HepG2 hepato cellular carcinoma cells33 prostates cancer34 
and breast cancer cells (MCF-7 and T47D)35. In cancer, 
chalcones disturbs the signal transduction pathway related 
to cellular proliferation, angiogenesis, metastasis, apoptosis, 
and the reversal multidrug resistant.36 In this study the 
structure of chalcones affected the anticancer and cancer 
selectivity of chalcones derivatives. Study of molecular 
mechanisms will be pursued in the further research to 
confirm the anticancer activity of chalcone derivatives 
compound 1-7 against leukemia cells. 
Conclusion
Dimethoxy group substitution in the position of carbon 
2,3,5 on the second phenyl ring can increase the anticancer 
activity of 4-amino-chalcones derivatives. The 4-amino-
chalcone derivatives with methoxy group in the position of 
carbon 2,3 on the second phenyl ring possess the highest 
selectivity toward HL-60 leukemia cancer cell lines 
among all the tested compounds. The results revealed that 
the number and position of methoxy groups in chalcone 
derivatives influenced the anticancer and cancer selectivity 
of chalcone derivatives. 
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